Veterinary Medicines

Carpcoat 8 mg film-coated tablets for dogs

Authorised
  • Carprofen
Download as PDF

Product identification

Medicine name:
Carpcoat 8 mg film-coated tablets for dogs
Carpcoat 8 mg filmomhulde tabletten voor honden
Active substance:
  • Carprofen
Target species:
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Carprofen
    8.00
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Film-coated tablet
Withdrawal period by route of administration:
  • Oral use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QM01AE91
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Netherlands
Package description:
  • (ID1) 10 Film-coated tablet: Box (board) with 1 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) with 10 Film-coated tablet, closed with (Aluminium)
  • (ID9) 90 Film-coated tablet: Box (board) with 9 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID6) 60 Film-coated tablet: Box (board) with 6 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID4) 40 Film-coated tablet: Box (board) with 4 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID8) 80 Film-coated tablet: Box (board) with 8 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID10) 100 Film-coated tablet: Box (board) with 10 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID11) 120 Film-coated tablet: Box (board) with 12 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID12) 250 Film-coated tablet: Box (board) with 25 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID5) 50 Film-coated tablet: Box (board) with 5 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID2) 20 Film-coated tablet: Box (board) with 2 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID3) 30 Film-coated tablet: Box (board) with 3 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)
  • (ID7) 70 Film-coated tablet: Box (board) with 7 Blister (polyvinyl chloride; polyethylene; polyvinylidene chloride) each with 10 Film-coated tablet, closed with (Aluminium)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Hybrid application – change in strength (Article 19(1)(a) of Regulation (EU) 2019/6)
Marketing authorisation holder:
  • Alfasan Nederland B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Alfasan Nederland B.V.
  • Lelypharma B.V.
Responsible authority:
  • Medicines Evaluation Board
Authorisation number:
  • REG NL 134082
Date of authorisation status change:
Reference member state:
  • Germany
Procedure number:
  • DE/V/0351/001
Concerned member states:
  • Austria
  • Belgium
  • Bulgaria
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Combined File of all Documents

This document does not exist in this language (English). You can find it in another language below.
Dutch (PDF)
Published on: 26/11/2025
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."